Great news! On April 1, 2026, a new oral GLP-1 therapy received FDA approval.
No more injections like Mounjaro or Ozempic — this new treatment comes in a tablet form, making it easier to use in everyday weight management and diabetes management.
Foundayo (Orforglipron) works by helping appetite control and blood sugar control. It may reduce hunger, help you feel full longer by slowing gastric emptying, and support better control of calorie intake.
It also helps the body manage blood sugar levels more steadily through improved glucose regulation and promotes healthy insulin release. Additionally, it can reduce cravings, which are important for sustainable weight loss and metabolic health.
Orforglipron vs Ozempic: Key Differences Between GLP-1 Medications
Unlike Ozempic, which is a subcutaneous injection, Orforglipron is an oral GLP-1 receptor agonist pill. This oral format offers more convenience, especially for those uncomfortable with injections or looking for a simpler way to support weight loss goals alongside diet and exercise.
Both medications target the body's natural hormone glucagon-like peptide-1 (GLP-1) pathway, promoting feelings of fullness and reducing appetite. Clinical studies show that they help decrease calorie intake and improve metabolic regulation, which are crucial for both type 2 diabetes treatment and weight management plans.
Insurance coverage and access may vary between these GLP-1 therapies, so discussing options with healthcare providers is recommended for an integrated approach incorporating lifestyle modifications and physical activity.
As with any medication, being aware of side effects and how to manage a missed dose is essential for safe and effective treatment.
Overall, Orforglipron's emergence represents a promising step in expanding weight loss treatments and offering alternatives within the growing class of compounded GLP-1s.
We are currently working with official suppliers, and the product should be available soon on HGHBangkok.com. Follow updates.
